Key result
Transcatheter valvular therapies and complex coronary interventions demonstrated favorable clinical outcomes across multiple 2019 trials, including a 46% reduction in the primary composite endpoint with TAVR in low-risk aortic stenosis.
Why the study?
The need for treatment strategies targeting complex structural heart and obstructive CAD is rapidly growing among older, higher-risk referral populations.
Provides a consolidated overview of pivotal 2019 clinical trials that expanded the evidence base for transcatheter structural heart and complex coronary interventions.
The need for treatment strategies targeting complex structural heart and obstructive epicardial coronary artery disease (CAD) is rapidly growing. The demographics in referral centers has shifted to an older population with greater co-morbidities and higher risk. Indeed, nearly one quarter of patients in tertiary-care settings have moderate or severe valvular heart disease, and despite a decrease in overall CAD burden in the United States over the past two decades the prevalence of myocardial infarction remains high. The 2019 societal scientific sessions included novel research and landmark presentations on less invasive valvular and safer complex coronary interventions in the aforementioned populations, in hopes of improving patient outcomes and expanding treatment indications. Transcatheter aortic valve replacement (TAVR), percutaneous mitral and tricuspid valve therapy, and complex coronary interventions, were the focus of important clinical trials and registry data. Herein, we provide a select and concise review of the most pivotal studies presented.
No takes yet. Share an insight, caveat, or question.
Lugo et al. (2020) conducted a review in Structural heart disease and complex coronary artery disease. Transcatheter valvular therapies and complex percutaneous coronary interventions vs. Standard surgical therapies or medical management was evaluated. Transcatheter valvular therapies and complex coronary interventions demonstrated favorable clinical outcomes across multiple 2019 trials, including a 46% reduction in the primary composite endpoint with TAVR in low-risk aortic stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: